Skip to main content
    M

    Mineralys Therapeutics, Inc. Common Stock (MLYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.48
    -0.05 (-0.34%)

    Market Cap: $1.29B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Mineralys Therapeutics, Inc. Common Stock (MLYS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market cap of $1.29B and an enterprise value of $1.28B. Its share count is up 26.05% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 0.23% below the market cap, as cash exceeds debt.

    Market Cap$1.29B
    Enterprise Value$1.28B
    Latest price (Nov 17, 2026)$14.48

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.03% in the quarter ended Sep 30, 2026 and grew 33.65% a year over 2 years.

    Shares Outstanding88.99M
    Shares Change (YoY)+26.05%
    Shares Change (QoQ)+5.03%
    Share Count Growth (2Y CAGR)+33.65%

    Price Statistics

    The stock is down 64.55% over 52 weeks and trades 34.33% below its 50-day average.

    Beta (1Y)1.62
    52-Week Change-64.55%
    1-Month Change-30.78%
    3-Month Change-46.27%
    6-Month Change-44.37%
    Total Return (1Y)-64.55%
    Total Return (3Y CAGR)+28.46%
    Return vs SPY (1Y)-78.19%
    Max Drawdown (1Y)-67.28%
    Max Drawdown (3Y)-69.41%
    Sharpe Ratio (1Y)-1.81
    Correlation with SPY (1Y)0.37
    50-Day Average$22.05
    200-Day Average$25.99
    52-Week Range$14.45 to $44.99
    RSI (14 Days)29.5
    Average Volume (20 Days)2.01M

    Price chart

    Financial Position

    Current assets cover 11.83x current liabilities, and total debt is 0.20x shareholder equity.

    Current Ratio11.83x
    Quick Ratio11.83x
    Debt / Equity0.20x

    Returns and Efficiency

    Return on invested capital is -51.14% and return on equity is -73.44% over the last 12 months.

    Return on Equity (ROE)-73.44%
    Return on Assets (ROA)-58.71%
    Return on Invested Capital (ROIC)-51.14%
    ROA (5Y Average)-67.76%

    Scores

    MLYS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$13.00K
    Operating Income-$389.75M
    Pretax Income-$369.97M
    Net Income-$369.97M
    Reported EPS (TTM)-$4.36

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.95% of the $630.12M in total assets.

    Cash and Equivalents$101.27M
    Total Debt$98.27M
    Net Cash$3.00M
    Net Cash Per Share$0.03
    Working Capital$574.92M
    Shareholder Equity$503.77M
    Book Value Per Share$5.66
    Total Assets$630.12M
    Total Liabilities$126.35M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$153.01M
    FCF Per Share-$1.73
    Depreciation and Amortization$17.53M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+15.54%
    Tangible Book Per Share Growth (2Y CAGR)+15.54%

    Revenue and profit by year

    Dividends and Yields

    MLYS does not pay a dividend.

    Buyback Yield-19.85%
    Shareholder Yield-19.85%

    Peer Position

    Against 4 similar companies, MLYS has the highest ROIC.

    ROIC-51.14% vs -65.50% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs +12.71% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MLYS

    What is MLYS's market cap?

    Mineralys Therapeutics, Inc. Common Stock has a market cap of $1.29B. Its enterprise value, which adds debt and subtracts cash, is $1.28B.

    How many shares of MLYS are outstanding?

    Mineralys Therapeutics, Inc. Common Stock has 88.99M shares outstanding. The count is up 26.05% from a year earlier.

    Does MLYS pay a dividend?

    No. Mineralys Therapeutics, Inc. Common Stock does not pay a dividend.

    How much debt does MLYS have?

    Mineralys Therapeutics, Inc. Common Stock has $98.27M of total debt and $101.27M of cash and equivalents, a net cash position of $3.00M.